钠-葡萄糖转运体2抑制剂辅助治疗成年人1型糖尿病的研究进展

1型糖尿病（T1DM）严重危害人们的健康和生命，但其经胰岛素降糖治疗后血糖达标率普遍偏低。长期使用胰岛素可导致频发低血糖、体质量增加和血压上升，进一步增加T1DM患者心血管事件发生风险。有研究显示新型降糖药物钠-葡萄糖转运体2（SGLT2）抑制剂辅助胰岛素治疗成年人T1DM可在减少胰岛素用量的同时进一步降低血糖，且不增加严重低血糖发生风险；但也有研究报道SGLT2抑制剂可增加成年T1DM患者糖尿病酮症酸中毒（DKA）发生风险。因此找到SGLT2抑制剂用于成年人T1DM的获益与风险的平衡点是临床研究的关键。本文汇总了近几年更新的关于SGLT2抑制剂用于成年人T1DM治疗的重要研究结果，对SGLT2抑制剂辅助胰岛素治疗成年人T1DM的获益与风险进行综述，以期为临床应用和未来研究提供参考。

Novel Developments in Sodium-glucose Co-transporter 2 Inhibitor for Adjuvant Therapy for Adult Type 1 Diabetics

Type 1 diabetes mellitus （T1DM） seriously endangers people's health and life.On the whole，insulin hypoglycemic therapy achieves low rate of meeting the target glucose level，and long-term use of insulin may lead to frequent hypoglycemia，increased body weight，and elevated blood pressure，further increasing the risk of cardiovascular events.Studies have shown that sodium-glucose co-transporter 2（SGLT2） inhibitor，a novel glucose-lowering drug，can be used as an adjuvant therapy for adult T1DM diabetics，which may reduce insulin dosage and blood glucose without increasing the risk of severe hypoglycemia.However，it has also been reported that SGLT2 inhibitors can increase the risk of diabetic ketoacidosis（DKA）.Therefore，finding out the balance between the benefits and risks of SGLT2 inhibitors for T1DM adults is the key to clinical research.This paper summarized recently achieved important research results regarding SGLT2 inhibitors for adult T1DM，with a detailed review of benefits and risks of SGLT2 inhibitors，offering a reference to related clinical application and research.